These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26170121)

  • 1. Amyloid imaging for dementia in clinical practice.
    O'Brien JT; Herholz K
    BMC Med; 2015 Jul; 13():163. PubMed ID: 26170121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias.
    Xia C; Dickerson BC
    PET Clin; 2017 Jul; 12(3):351-359. PubMed ID: 28576172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current and future prospects of nuclear medicine in dementia].
    Ito K; Inui Y; Kizawa T; Kimura Y; Kato T
    Rinsho Shinkeigaku; 2017 Sep; 57(9):479-484. PubMed ID: 28804110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
    Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.
    Shea YF; Ha J; Lee SC; Chu LW
    Hong Kong Med J; 2016 Aug; 22(4):327-33. PubMed ID: 27313272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.
    Del Sole A; Malaspina S; Magenta Biasina A
    Funct Neurol; 2016; 31(4):205-215. PubMed ID: 28072381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
    de Lartigue J
    Drugs Today (Barc); 2014 Mar; 50(3):219-29. PubMed ID: 24696867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias.
    Taswell C; Villemagne VL; Yates P; Shimada H; Leyton CE; Ballard KJ; Piguet O; Burrell JR; Hodges JR; Rowe CC
    J Nucl Med; 2015 Oct; 56(10):1547-53. PubMed ID: 26251415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Amyloid Positron Emission Tomography in the Therapeutic Strategies for Alzheimer's Disease].
    Ishii K
    Brain Nerve; 2017 Jul; 69(7):809-818. PubMed ID: 28739995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography imaging in dementia.
    Herholz K; Carter SF; Jones M
    Br J Radiol; 2007 Dec; 80 Spec No 2():S160-7. PubMed ID: 18445746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education.
    Johnson KA; Minoshima S; Bohnen NI; Donohoe KJ; Foster NL; Herscovitch P; Karlawish JH; Rowe CC; Hedrick S; Pappas V; Carrillo MC; Hartley DM
    J Nucl Med; 2013 Jul; 54(7):1011-3. PubMed ID: 23753186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signs and Artifacts in Amyloid PET.
    Lundeen TF; Seibyl JP; Covington MF; Eshghi N; Kuo PH
    Radiographics; 2018; 38(7):2123-2133. PubMed ID: 30422768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of brain amyloid in dementia: a review.
    Quigley H; Colloby SJ; O'Brien JT
    Int J Geriatr Psychiatry; 2011 Oct; 26(10):991-9. PubMed ID: 21905095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.
    Rabinovici GD; Karlawish J; Knopman D; Snyder HM; Sperling R; Carrillo MC
    Alzheimers Dement; 2016 Apr; 12(4):510-5. PubMed ID: 27103054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of β-amyloid positron emission tomography on the diagnostic and treatment decisions of dementia experts.
    Ganz ML; Tawah AF; Guo S; Chitnis AS; Silies H; Schäuble B; Jovalekic A; Foster NL
    Neurodegener Dis Manag; 2017 Apr; 7(2):107-117. PubMed ID: 28445082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular imaging of dementia.
    Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
    Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Visualization of amyloid with positron emission tomography. Useful improvement in the diagnosis of dementia?].
    Grimmer T; Drzezga A; Kurz A
    Nervenarzt; 2010 May; 81(5):602-6. PubMed ID: 20221742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Use and Utility of Amyloid Imaging.
    Barthel H; Sabri O
    J Nucl Med; 2017 Nov; 58(11):1711-1717. PubMed ID: 28818990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.